Carl Icahn (Heidi Gutman/CNBC/NBCU Photo Bank/NBCUniversal via Getty Images)
March 13, 2023 07:19 AM EDTUpdated 02:16 PM
People
Startups

Up­dat­ed: Carl Ic­ahn pro­pos­es three new Il­lu­mi­na board mem­bers in proxy fight

Kyle LaHucik

Senior Reporter

A proxy fight is brew­ing at Il­lu­mi­na as ac­tivist in­vestor Carl Ic­ahn ar­gues that the DNA se­quenc­ing gi­ant is cost­ing share­hold­ers bil­lions by fol­low­ing through …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

A service from the Financial Times